National Conference of the Italian Group for the Study of Neuromorphology
Vol. 70 No. s2 (2026): 36th National Conference of the Italian Group for the Study of...

P001 | A MILLIFLUIDIC GLIOBLASTOMA MODEL TO INVESTIGATE HYPOXIA-DRIVEN SECRETOME REMODELLING AND ITS MODULATION BY PACAP

A.G. D’Amico1|3, D.M. Rasà2, G. Maugeri3, N. Palmeri3, V. D’Agata3 | 1Department of Drug and Health Sciences, University of Catania, Italy; 2Department of Medicine and Surgery, Kore University of Enna, Italy; 3Section of Anatomy, Histology and Movement Sciences, Department of Biomedical and Biotechnological Sciences, University of Catania, Italy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 November 2026
0
Views
0
Downloads

Authors

Glioblastoma (GBM) remains the most lethal primary brain malignancy, with therapeutic resistance largely driven by glioblastoma stem cells, which reside in specialized tumor niches. This microenvironment is sustained by growth factor and cytokine secretion, which alters the tumor secretome and promotes cancer cell pluripotency, invasiveness, tumor dissemination, and chemotherapy resistance. To investigate these dynamics, we set up a 3D millifluidic platform (MIVO) that replicates the tumor-microcirculation interface. This system features a compartmentalized architecture in which a porous, permeable membrane separates a GBM tumorspheres chamber from a dynamic fluidic compartment, simulating dissemination of the systemic secretome. We validated the platform using immortalized GBM cell lines (T98G, A172 and U118MG). Hypoxia induction via deferoxamine (DFX) significantly altered the secretome profile in a cell-specific manner, increasing vascular endothelial growth factor (VEGF) in all models and interleukin-1β (IL-1β) levels in A172 and U118MG tumorspheres compared to normoxic controls. PACAP treatment significantly reduced VEGF concentrations in the circulating compartment of all models and brought IL-1β back towards control levels in A172 and U118MG tumorspheres. These data highlight the platform's ability to detect secretome remodelling and its pharmacological modulation. Overall, the 3D millifluidic system captures pathophysiological transitions of the GBM secretome, providing a tool for mechanistic studies and screening of therapeutic agents targeting the hypoxic tumor niche.

Downloads

Download data is not yet available.

Citations

How to Cite



1.
P001 | A MILLIFLUIDIC GLIOBLASTOMA MODEL TO INVESTIGATE HYPOXIA-DRIVEN SECRETOME REMODELLING AND ITS MODULATION BY PACAP: A.G. D’Amico1|3, D.M. Rasà2, G. Maugeri3, N. Palmeri3, V. D’Agata3 | 1Department of Drug and Health Sciences, University of Catania, Italy; 2Department of Medicine and Surgery, Kore University of Enna, Italy; 3Section of Anatomy, Histology and Movement Sciences, Department of Biomedical and Biotechnological Sciences, University of Catania, Italy. Eur J Histochem [Internet]. 2026 Nov. 20 [cited 2026 Nov. 20];70(s2). Available from: https://www.ejh.it/ejh/article/view/4821